CARDIFF LEXINGTN CORP - CDIX STOCK NEWS

Cardiff Lexington (OTC PINK:CDIX) has announced its financial results for Q2 and H1 2024. Key highlights include:

- Q2 revenue of $2,330,964 with a 66% gross profit margin
- H1 revenue of $4,992,930 with a 65% gross profit margin
- Shareholders' equity increased by 698% to $5,837,412
- Cash increased by 269% to $3,196,795
- Total assets increased by 19% to $24,659,020

The company reported a loss from continuing operations of $202,345 in Q2, partly due to increased bad debt expense. However, for H1, income from continuing operations was $16,647. Cardiff Lexington is focusing on expanding its healthcare locations, having opened its 12th Nova Ortho and Spine location in Orlando, Florida.

Cardiff Lexington (OTC Pink:CDIX) has announced the opening of its 12th Nova Ortho and Spine location in Orlando, Florida, set to open on August 5, 2024. This new 1,600 square foot facility marks the company's 11th location in Florida and establishes a presence in the state's fourth-largest city. Nova Ortho and Spine specializes in providing diagnostic and surgical services for traumatic injury victims, with revenue primarily derived from various insurance policies.

CEO Alex Cunningham emphasized that this expansion aligns with the company's growth strategy, enhancing visibility and patient access in larger metropolitan areas. Dr. Kevin Fitzgerald, Managing Director of Nova Ortho and Spine, highlighted the company's strong referral source and high patient satisfaction ratings as key factors in choosing Orlando for their newest location.

Cardiff Lexington (OTC PINK: CDIX) announced the cancellation of its Senior Secured Convertible Promissory Note, 8% Convertible Secured Redeemable Note, and series R preferred stock through an agreement with GHS Investments. In exchange, a new fixed amount settlement promissory note of $535,000 was issued, which bears no interest and requires fixed payments. CEO Alex Cunningham highlighted the elimination of convertible debt as a significant step towards simplifying and strengthening the company's capital structure. The company reported sequential revenue growth, a strong gross margin of 64% in Q1 2024, and a net income of $3 million for the full year 2023.

Cardiff Lexington (OTC Pink: CDIX) announced on June 11, 2024, the appointment of Shannon Vitale as controller and LaTanga Hickman as staff accountant to enhance its financial operations and support anticipated growth. Vitale brings over 15 years of experience in accounting and compliance, previously holding roles at Energy Focus and The NRP Group. Hickman, with over a decade of experience, has worked in various sectors including real estate and healthcare, most recently at Gas Xpress Development. The company aims to strengthen its finance team and drive strategic initiatives with these new additions. The role of chief accounting officer has been eliminated, and Zia Choe has left the company.

Cardiff Lexington (CDIX) reported a 12% sequential revenue growth in the first quarter of 2024, with a 64% gross profit margin. The operating income decreased due to scaling expenses and stock compensation, but excluding these, it showed a 48% sequential increase. The company is focused on strategic investments to support future growth and aims to uplist to a major U.S. exchange. With improved balance sheet metrics, Cardiff Lexington aims to expand its market presence and drive long-term growth.

Cardiff Lexington (CDIX) reports strong financial results for the fourth quarter and full year 2023, showing significant revenue growth, improved profitability, and positive balance sheet highlights. The company's operating income, net income, and EBITDA all experienced substantial increases, with a focus on expanding their healthcare subsidiary, Nova Ortho and Spine, to capitalize on market demand.

Cardiff Lexington Corporation (CDIX) announces the opening of a new Nova Ortho and Spine location in Valdosta, Georgia, marking a significant milestone in their growth strategy. This expansion outside of Florida into the broader Southeast region of the United States signifies the company's commitment to providing diagnostic and surgical services for traumatic injury victims. Dr. Kevin Fitzgerald, the newly appointed Managing Director, will oversee the Valdosta location, with plans for further expansion across Georgia and the Southeast.

Cardiff Lexington Corporation (CDIX) appoints Dr. Kevin Fitzgerald, M.D. as Managing Director of Nova Ortho and Spine, their healthcare subsidiary. Dr. Fitzgerald brings over 20 years of medical experience and will oversee day-to-day operations, expansion, patient care, provider production, marketing, and company relations. The company expects accelerated growth with Dr. Fitzgerald's leadership.

Cardiff Lexington Corporation (CDIX) implements a 75,000-to-1 reverse stock split to list its common stock on a national securities exchange. The company's third quarter showed revenue growth, gross margin improvement, and pre-tax net income of approximately $2.0 million. The company is simplifying its capital structure to align share count and public float with its strong operating business, with preferred stockholders committed to converting their shares to common stock. The split aims to strengthen the company's capitalization, support growth, and enhance exposure and liquidity in the public markets.